深静脉血栓形成

Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e195S-e226S.

• 全文
• 摘要

Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.

• 全文
• 摘要

Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.

• 摘要

Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.

• 全文
• 摘要

1.  Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-463.

• 摘要

2.  White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I4-I8.

• 全文
• 摘要

3.  White RH, Zhou H, Murin S, et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93:298-305.

• 摘要

4.  James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2009:277-285.

• 全文
• 摘要

5.  Marder VJ, Rosove MH, Minning DM. Foundation and sites of action of antithrombotic agents. Best Pract Res Clin Haematol. 2004;17:3-22.

• 摘要

6.  Geddings JE, Mackman N. Tumor derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013;122:1873-1880.

• 全文
• 摘要

7.  Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis. 2008;25:37-44.

• 摘要

8.  Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325:887-890.

• 全文
• 摘要

9.  Cogo A, Lensing AW, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep vein thrombosis: implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993;153:2777-2780.

• 摘要

10.  Kageyama N, Ro A, Tanifuji T, et al. Significance of the soleal vein and its drainage veins in cases of massive pulmonary thromboembolism. Ann Vasc Dis. 2008;1:35-39.

• 全文
• 摘要

11.  Kearon C, Ginsberg JS, Douketis J, et al. A new and improved system for excluding the diagnosis of deep venous thrombosis. Ann Intern Med. 2001;135:S-24.

• 摘要

12.  Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62:126-136.

• 摘要

13.  White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446.

• 摘要

14.  Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or post-partum: a 30 year population-based study. Ann Intern Med. 2005;143:697-706.

• 摘要

15.  Turpie AG, Chin BS, Lip GY. ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies. BMJ. 2002;325:948-950.

• 全文
• 摘要

16.  Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and the risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94:17-25.

• 摘要

17.  Langlois NJ, Wells PS. Risk of venous thromboembolism in relatives of symptomatic probands with thrombophilia: a systematic review. Thromb Haemost. 2003;90:17-26.

• 摘要

18.  Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.

• 全文
• 摘要

19.  Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050-1057.

• 全文
• 摘要

20.  Brouwer J-LP, Bijl M, Veeger NJGM, et al. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood. 2004;104:143-148.

• 全文
• 摘要

21.  Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e195S-e226S.

• 全文
• 摘要

22.  Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:131-134.

• 全文
• 摘要

23.  Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.

• 全文
• 摘要

24.  Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011;63:877-883.

• 摘要

25.  Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e227S-e277S.

• 全文
• 摘要

26.  Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e278S-e325S.

• 全文
• 摘要

27.  Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.

• 全文
• 摘要

28.  Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721-729.

• 摘要

29.  Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.

• 全文
• 摘要

30.  Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.

• 摘要

31.  Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.

• 摘要

32.  Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.

• 全文
• 摘要

33.  RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.

• 摘要

34.  Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-1680.

• 摘要

35.  Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.

• 全文
• 摘要

36.  Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807-815.

• 摘要

37.  Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-2498.

• 全文
• 摘要

38.  Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513-523.

• 全文
• 摘要

39.  Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167-2177.

• 全文
• 摘要

40.  Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8-18.

• 摘要

41.  Galanis T, Eraso L, Perez A, et al. Venous thromboembolic disease. In: Slovut DP, Dean SM, Jaff MR, et al, eds. Comprehensive review in vascular and endovascular medicine. Vol I. Minneapolis, MN: Cardiotext Publishing; 2012:251-284.

42.  Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ. 2003;326:1180-1184.

• 摘要

43.  Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006;332:215-219.

• 全文
• 摘要

44.  Scarvelis D, Wells PS. Diagnosis and treatment of deep-vein thrombosis. CMAJ. 2006;175:1087-1092.

• 全文
• 摘要

45.  Lucassen W, Geersing GJ, Erkens PM, et al. Clinical decision rules for excluding pulmonary embolism: a meta-analysis. Ann Intern Med. 2011;155:448-460.

• 摘要

46.  Kruip MJ, Slob MJ, Schijen JH, et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med. 2002;162:1631-1635.

• 全文
• 摘要

47.  Prandoni P, Barbar S, Milan M, et al. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. Eur J Intern Med. 2014;25:25-30.

• 全文
• 摘要

48.  Bernardi E, Camporese G, Büller HR, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deep vein thrombosis: a randomized controlled trial. JAMA. 2008;300:1653-1659.

• 全文
• 摘要

49.  Johnson SA, Stevens SM, Woller SC, et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA. 2010;303:438-445.

• 摘要

50.  Ten Cate-Hoek AJ, Prins MH. Management studies using a combination of D-dimer test result and clinical probability to rule out venous thromboembolism: a systematic review. J Thromb Haemost. 2005;3:2465-2670.

• 摘要

51.  Remy-Jardin M, Remy J, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology. 1996;200:699-706.

• 摘要

52.  Lensing AW, Doris CI, McGrath FP, et al. A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. Arch Intern Med. 1997;157:765-768.

• 摘要

53.  Chan WS, Spencer FA, Ginsbergm JS. Anatomic distribution of deep vein thrombosis in pregnancy. CMAJ. 2010;182:657-660.

• 全文
• 摘要

54.  Francalanci I, Comeglio P, Liotta AA, et al. D-dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res. 1995;78:399-405.

• 摘要

55.  Chan WS, Chunilal S, Lee A, et al. A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med. 2007;147:165-170.

• 摘要

56.  Chan WS, Lee A, Spencer FA, et al. Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med. 2009;151:85-92.

• 摘要

57.  Chan WS, Spencer FA, Lee AY, et al. Safety of withholding anticoagulation in pregnant women with suspected deep vein thrombosis following negative serial compression ultrasound and iliac vein imaging. CMAJ. 2013;185:E194-E200.

• 全文
• 摘要

58.  Le Gal G, Prins AM, Righini M, et al. Diagnostic value of a negative single complete compression ultrasound of the lower limbs to exclude the diagnosis of deep venous thrombosis in pregnant or postpartum women: a retrospective hospital-based study. Thromb Res. 2006;118:691-697.

• 摘要

59.  Ratiu A, Navolan D, Spatariu I, et al. Diagnostic value of a negative single color duplex ultrasound in deep vein thrombosis suspicion during pregnancy. Rev Med Chir Soc Med Nat Iasi. 2010;114:454-456.

• 摘要

60.  Bates SM, Jaeschke R, Stevens SM, et al; American College of Chest Physicians. Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis (9th ed): American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e351S-e418S.

• 全文
• 摘要

61.  Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712-1723.

• 摘要

62.  Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884-889.

• 全文
• 摘要

63.  Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401-410.

• 摘要

64.  National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. November 2015. http://www.nice.org.uk (last accessed 16 September 2017).

• 全文

65.  Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism: a national clinical guideline. December 2010. http://www.sign.ac.uk (last accessed 29 June 2016).

• 全文

66.  Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352-2361.

• 摘要

67.  Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.

• 摘要

68.  Geersing GJ, Janssen KJ, Oudega R, et al. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. BMJ. 2009;339:b2990.

• 全文
• 摘要

69.  Fancher TL, White RH, Kravitz RL. Combined use of rapid D-dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ. 2004;329:821.

• 全文
• 摘要

70.  Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med. 2001;135:108-111.

• 摘要

71.  Segal JB, Eng J, Tamariz LJ, et al. Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. Ann Fam Med. 2007;5:63-73.

• 全文
• 摘要

72.  Thomas SM, Goodacre SW, Sampson FC, et al. Diagnostic value of CT for deep vein thrombosis: results of a systematic review and meta-analysis. Clin Radiol. 2008;63:299-304.

• 摘要

73.  Cohn DM, Vansenne F, de Borgie CA, et al. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;(12):CD007069.

• 全文
• 摘要

74.  Gorman WP, Davis KR, Donnelly R. ABC of arterial and venous disease. Swollen lower limb-1: general assessment and deep vein thrombosis. BMJ. 2000;320:1453-1456.

• 全文
• 摘要

75.  White RH, McGahan JP, Daschbach MM, et al. Diagnosis of deep-vein thrombosis using duplex ultrasound. Ann Intern Med. 1989;111:297-304.

• 摘要

76.  Di Nisio M, Van Sluis GL, Bossuyt PM, et al. Accuracy of diagnostic tests for clinically suspected upper extremity deep vein thrombosis: a systematic review. J Thromb Haemost. 2010;8:684-692.

• 摘要

77.  Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003;2:148-157.

• 摘要

78.  Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for occult cancer in unprovoked venous thromboembolism. N Engl J Med. 2015;373:697-704.

• 全文
• 摘要

79.  Qaseem A, Chou R, Humphrey LL, et al; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;155:625-632.

• 全文
• 摘要

80.  Nordenholz K, Ryan J, Atwood B, et al. Pulmonary embolism risk stratification: pulse oximetry and pulmonary embolism severity index. J Emerg Med. 2011;40:95-102.

• 全文
• 摘要

81.  Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041-1046.

• 全文
• 摘要

82.  Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11:e442-e444.

• 全文
• 摘要

83.  Akl EA, Rohilla S, Barba M, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer. 2008;113:1685-1794.

• 摘要

84.  National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolism. June 2017. http://www.nccn.org (last accessed 18 September 2017).

• 全文

85.  Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064-1083.

• 摘要

86.  Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: acute management. April 2015. http://www.rcog.org.uk (last accessed 18 September 2017).

• 全文

87.  Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.

• 全文
• 摘要

88.  Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.

• 摘要

89.  Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.

• 全文
• 摘要

90.  Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.

• 全文
• 摘要

91.  Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369:2304-2312.

• 摘要

92.  Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294-2303.

• 摘要

93.  Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283-2293.

• 摘要

94.  Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing: recalibrating expectations. N Engl J Med. 2013;369:2273-2275.

• 摘要

95.  Middeldorp S, Prins MH, Hutten BA. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2014;(8):CD001367.

• 全文
• 摘要

96.  Noble SI, Shelley MD, Coles B, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:577-584.

• 摘要

97.  Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl):e419S-e494S.

• 全文
• 摘要

98.  Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009;123:837-844.

• 摘要

99.  Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;(7):CD006650.

• 全文
• 摘要

100.  Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS study. J Clin Oncol. 2014;32:3607-3612.

• 摘要

101.  Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: a systematic review. Thromb Res. 2008;122:763-773.

• 摘要

102.  Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, et al. Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. Int Angiol. 2008;27:494-499.

• 摘要

103.  Aissaoui N, Martins E, Mouly S, et al. A meta-analysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both. Int J Cardiol. 2009;137:37-41.

• 摘要

104.  Anderson CM, Overend TJ, Godwin J, et al. Ambulation after deep vein thrombosis: a systematic review. Physiother Can. 2009;61:133-140.

• 全文
• 摘要

105.  Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160:769-774.

• 全文
• 摘要

106.  Levine M, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.

• 摘要

107.  Kuruvilla J, Wells PS, Morrow B, et al. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost. 2003;89:284-287.

• 摘要

108.  Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006:408-414.

• 全文
• 摘要

109.  Gage BF, Fihn SD, White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med. 2001;134:465-474.

• 摘要

110.  Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost. 2006;96:274-284.

• 摘要

111.  US Food and Drug Administration. Removing retrievable inferior vena cava filters: FDA safety communication. May 2014. http://www.fda.gov (last accessed 19 September 2017).

• 全文

112.  Vedantham S, Millward SF, Cardella JF, et al. Society of Interventional Radiology position statement: treatment of acute iliofemoral deep vein thrombosis with use of adjunctive catheter-directed intrathrombus thrombolysis. J Vasc Interv Radiol. 2009;20(7 suppl):S332-S335.

• 摘要

113.  Vedantham S, Sista AK, Klein SJ, et al; Society of Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe Standards of Practice Committees. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014;25:1317-1325.

• 全文
• 摘要

114.  Gogalniceanu P, Johnston CJ, Khalid U, et al. Indications for thrombolysis in deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009;38:192-198.

• 摘要

115.  Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood. 2008;112:4432-4436.

• 全文
• 摘要

116.  Vedantham S. Deep venous thrombosis: the opportunity at hand. AJR Am J Roentgenol. 2009;193:922-927.

• 全文
• 摘要

117.  Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspect Vasc Surg Endovasc Ther. 2009;21:221-224.

• 摘要

118.  Carrier M, Le Gal G, Wells PS, et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578-589.

• 摘要

119.  Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009;28:401-409.

• 摘要

120.  Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.

• 全文
• 摘要

121.  Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995;332:1661-1665.

• 摘要

122.  Schulman S, Granqvist S, Holmström M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997;336:393-398.

• 摘要

123.  Kearon C. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated. J Thromb Thrombolysis. 2011;31:295-300.

• 摘要

124.  Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009;150:577-585.

• 摘要

125.  Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112:511-515.

• 全文
• 摘要

126.  Cosmi B, Legnani C, Tosetto A, et al. Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis. 2009;28:381-388.

• 摘要

127.  Cosmi B, Legnani C, Iorio A, et al. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. Eur J Vasc Endovasc Surg. 2010;39:356-365.

• 摘要

128.  Meijer K, Schulman S. The absence of 'minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. J Thromb Haemost. 2009;7:1619-1628.

• 摘要

129.  Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417-426.

• 全文
• 摘要

130.  Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.

• 摘要

131.  Huisman MV, Buller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989;95:498-502.

• 全文
• 摘要

132.  Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost. 2006;32:838-847.

• 摘要

133.  Kahn SR, Kearon C, Julian JA, et al. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005;3:718-723.

• 摘要

134.  White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107:414-424.

• 摘要

135.  Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.

• 摘要

136.  Dager WE, King JH, Regalia RC, et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy. 2006;26:1091-1098.

• 摘要

137.  Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154:516-522.

• 摘要

138.  Lefkou E, Khamashta M, Hampson G, et al. Review: low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus. 2010;19:3-12.

• 摘要

139.  Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008;42:979-988.

• 摘要

140.  INR self-monitoring and oral anticoagulants. Prescrire Int. 2010;19:130-132.

• 摘要

141.  Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257-2264.

• 全文
• 摘要